Cancer immunotherapy: an evolving paradigm

查看全文 作　　者：Aifu [1,2,3]LIN

机构地区：[1]MOE Laboratory of Biosystem Homeostasis and Protection,College of Life Sciences,Zhejiang University,Hangzhou 310058,China;[2]Cancer Center,Zhejiang University,Hangzhou 310058,China;[3]Key Laboratory for Cell and Gene Engineering of Zhejiang Province,Hangzhou 310058,China

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》索引2022年第23卷第10期,共2页

摘　　要：The inhibition of the host’s natural immune response by tumor cells was widely reported in the early phases of the development of oncology therapy,and the concept of employing the host’s immune system to treat cancer,i.e.tumor immunotherapy,is not new.However,as a result of early theoretical constraints,clinical application of immunotherapy did not go smoothly and lagged significantly behind radiation and chemotherapy.The path has been winding,but the future now seems promising.Immunotherapy research has advanced enormously as a result of the maturing of immuno-editing theory and the creation of numerous technologies,despite a number of unsuccessful endeavors and clinical studies.Since around 1998,the US Food and Drug Administration(FDA)has approved a variety of tumor immunotherapies,including cytokines(interleukin-2,interferons),cancer vaccines(Provenge),immune checkpoint inhibitors(ipilimumab),and cellular therapies(chimeric antigen receptor-T(CAR-T)),signaling a boom in the field. 关键词：IMMUNOTHERAPY CLINICAL CHEMOTHERAPY

相关文献

参考文献（6）
引证文献（1）
耦合文献（21）

参考文献(6)

引证文献(1)

耦合文献(21)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Cancer immunotherapy: an evolving paradigm

参考文献(6)

引证文献(1)

耦合文献(21)

用户提示